#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16076	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2088	762.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1397	1397	C	925	C	854	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29236	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3538	823.6	0	.	n	.	0	T695C	SNP	695	695	T	1051	1051	C	896	C,T	843,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29236	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3538	823.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1693	1693	A	1013	A,G,T	941,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29236	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3538	823.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2327	2327	C	938	C,T	872,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29236	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3538	823.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2953	2953	T	885	T	831	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29236	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3538	823.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2401	2401	A	980	A	916	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1948	folP	852	852	100.0	folP.l15.c30.ctg.1	1694	114.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1029	1031	AGC	200;194;192	A;G;C	190;186;183	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5140	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3377	151.8	1	SNP	p	S91F	0	.	.	271	273	TCC	597	599	TCC	178;179;177	T;C;C	167;170;169	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5140	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3377	151.8	1	SNP	p	D95G	0	.	.	283	285	GAC	609	611	GAC	179;180;179	G;A;C	168;169;169	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5140	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3377	151.8	1	SNP	p	D95N	0	.	.	283	285	GAC	609	611	GAC	179;180;179	G;A;C	168;169;169	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	1686	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1538	109.2	1	SNP	p	G45D	1	.	.	133	135	GAC	642	644	GAC	220;219;224	G,T;A,T;C	197,1;192,1;203	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	854	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	993	85.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5374	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3010	178.0	1	SNP	p	D86N	0	.	.	256	258	GAC	614	616	GAC	212;212;212	G;A;C	199;199;199	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5374	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3010	178.0	1	SNP	p	S87I	0	.	.	259	261	AGT	617	619	AGT	213;214;214	A;G,T;T	196;197,1;200	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5374	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3010	178.0	1	SNP	p	S87R	0	.	.	259	261	AGT	617	619	AGT	213;214;214	A;G,T;T	196;197,1;200	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5374	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3010	178.0	1	SNP	p	S87W	0	.	.	259	261	AGT	617	619	AGT	213;214;214	A;G,T;T	196;197,1;200	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5374	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3010	178.0	1	SNP	p	S88P	0	.	.	262	264	TCC	620	622	TCC	214;215;217	T;C;C	200;201;199	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4362	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2805	155.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1620	1622	GGC	221;222;219	G;G;C	203;204;203	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	0	.	p	.	0	M35I	NONSYN	103	105	ATG	389	391	ATA	218;220;219	A;T;A	199;199;199	.	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	0	.	p	.	0	C41G	NONSYN	121	123	TGT	407	409	GGT	220;223;227	G;G;T,A	203;208;205,1	.	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	0	.	p	.	0	A70T	NONSYN	208	210	GCA	494	496	ACA	233;231;228	A;C;A	211;210;210	.	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	0	.	p	.	0	D101E	NONSYN	301	303	GAT	587	589	GAG	197;197;197	G;A;G	182;182;185	.	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	0	.	p	.	0	V122I	NONSYN	364	366	GTC	650	652	ATT	203;205;206	A;T;T	189;191;193	.	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	0	.	p	.	0	Y201H	NONSYN	601	603	TAT	887	889	CAT	189;190;191	C;A;T	178;178;175	.	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	0	.	p	.	0	Q230K	NONSYN	688	690	CAA	974	976	AAA	186;186;185	A;A;A,C	173;175;173,1	.	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	0	.	p	.	0	L447V	NONSYN	1339	1341	CTC	1625	1627	GTC	177;179;179	G,C;T;C	167,1;166;168	.	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	0	.	p	.	0	V515I	NONSYN	1543	1545	GTC	1829	1831	ATC	177;180;177	A;T;C	168;169;168	.	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	1	SNP	p	P551S	1	P551S	NONSYN	1651	1653	CCG	1937	1939	TCG	205;203;199	T,G;C;G	130,11;162;162	penA.0.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1217	1219	GCA	196;195;194	G;C;A	175;177;181	penA.0.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1220	1222	ATC	196;193;197	A;T;C	180;178;183	penA.0.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1232	1234	GTG	199;195;191	G;T;G	186;180;177	penA.0.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1232	1234	GTG	199;195;191	G;T;G	186;180;177	penA.0.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1733	1735	ACC	197;191;191	A;C,A;C	180;177,1;175	penA.0.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1787	1789	GCG	191;194;191	G;C;G	160;156;155	penA.0.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1787	1789	GCG	191;194;191	G;C;G	160;156;155	penA.0.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	539	3954	penA	1746	1746	97.88	penA.l6.c4.ctg.1	2444	161.0	1	SNP	p	G545S	0	.	.	1633	1635	GGC	1919	1921	GGC	190;189;189	G;G;C	178;178;176	penA.0.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5702	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3200	177.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2172	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1871	115.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	585	585	C	180	C	162	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	G38E	NONSYN	112	114	GGA	307	309	GAA	239;240;238	G;A;A	228;230;227	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	337	339	GGA	236;236;237	G;G;A	222;225;226	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	T87A	NONSYN	259	261	ACT	454	456	GCT	249;249;248	G;C;T	231;232;229	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	T89S	NONSYN	265	267	ACC	460	462	AGC	253;253;255	A;G;C	239;237;240	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	.	MULTIPLE	358	359	AA	552	553	CG	213;214	C;G	203;203	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	.	MULTIPLE	361	362	GA	555	557	CAG	218;218;219	C;A;G	205;206;205	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	559	561	AAA	215;214;213	A;A;A	203;203;203	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	K143E	NONSYN	427	429	AAA	622	624	GAA	243;240;238	G,A;A;A	229,2;227;226	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	646	648	GCA	253;256;256	G;C,T;A	239;241,1;241	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	N212D	NONSYN	634	636	AAT	829	831	GAT	214;213;211	G;A;T	203;204;202	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	D213G	NONSYN	637	639	GAT	832	834	GGT	207;207;202	G;G;T	198;198;192	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	I218M	NONSYN	652	654	ATA	847	849	ATG	200;201;201	A;T;G,C	191;190;188,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	R258H	NONSYN	772	774	CGT	967	969	CAT	251;255;256	C;A,G;T	234;239,1;238	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1030	1032	GTA	272;269;269	G;T;A	254;251;249	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1069	1071	ACT	291;292;292	A;C;T,A,C	266;269;270,1,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1075	1077	GAT	291;289;289	G,A;A;T	270,1;268;271	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1087	1089	CAC	291;293;293	C;A;C	269;272;276	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	1	SNP	p	G120K	1	.	.	358	360	AAG	552	554	CGG	213;214;216	C;G;G	203;203;202	porB1b.WHO_Z_02266c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	1	SNP	p	A121D	1	.	.	361	363	GAC	555	558	CGC	218;219;215	C;G;C	205;205;201	porB1b.WHO_Z_02266c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3000	porB1b	1047	1047	97.52	porB1b.l15.c17.ctg.1	1385	214.2	1	SNP	p	D121N	0	.	.	361	363	GAC	555	558	CGC	218;219;215	C;G;C	205;205;201	porB1b.WHO_Z_02266c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11772	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4981	235.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2018	2020	AAT	222;222;220	A;A;T	206;205;206	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1276	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1070	118.5	1	SNP	p	V57M	1	.	.	169	171	ATG	518	520	ATG	253;250;252	A;T;G,T	231;231;230,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
